Our latest video in our partnership with @DGlaucomflecken summarizes new research into therapy for atrial fibrillation in patients with drug-eluting stents. Read the full study for free: nej.md/DrG36 #AFib
Presented at #ISICEM:
Among patients with traumatic hemorrhage, prehospital whole-blood transfusion was not superior to standard transfusion with red-cell and plasma components in reducing the risk of death or massive transfusion. Full phase 3 SWiFT trial results: https://www.nejm.org/doi/full/10.1056/NEJMoa2516043
@ISICEM
Presented at #ISICEM:
In a multicenter trial involving patients with acute hypoxemic respiratory failure, 28-day mortality with high-flow oxygen was not significantly different from that with standard oxygen. Full SOHO trial results: https://www.nejm.org/doi/full/10.1056/NEJMoa2516087
Editorial: Rethinking High-Flow Oxygen in Acute Hypoxemic Respiratory Failure https://www.nejm.org/doi/full/10.1056/NEJMe2602037
@ISICEM
A new review summarizes advances in radiotherapy that reduce injury to normal tissue, including improvements in the precision of imaging and delivery, and outlines strategies to prevent and manage treatment-related side effects. Read the full review: https://www.nejm.org/doi/full/10.1056/NEJMra2506017
Science behind the Study: Gene Therapy to Treat Profound Hearing Loss https://www.nejm.org/doi/full/10.1056/NEJMe2514326
#Genetics #Otolaryngology
Perspective by @AbbasHassanMD, PhD, and Jennifer F. Waljee, MD, MPH: Valuing Care Provided by Residents and Fellows — Toward Competency-Based Billing https://www.nejm.org/doi/full/10.1056/NEJMp2514693
#HealthPolicy #MedEd
Artificial Intelligence in the Clinic: Don’t Pay for the Tool, Pay for the Care https://nej.md/3ZEpqYr
Is apixaban safer than rivaroxaban for acute venous thromboembolism (VTE)?
NEJM Clinician Editor-in-Chief, Raja-Elie Abdulnour, MD (@BageLeMage), describes the first head-to-head trial comparing the bleeding risks of these two direct-acting oral anticoagulants. Read the context and comment by Christopher W. Goodman, MD: https://jwat.ch/4doeoye
See What Changes Practice This Week in @NEJMClinician:
🔬 Guideline Watch: Caring for Adults Hospitalized with Inflammatory Bowel Disease
🦇 Clinical Conversations: @PaulSaxMD on Rabies
🧠 When to Consider Osmotic Demyelination Syndrome without Hyponatremia
📊 Predicting Outcomes in Metabolic Dysfunction–Associated Steatotic Liver Disease
The diagnosis of polymyalgia rheumatica is made on the basis of clinical grounds by combining characteristic signs and symptoms with laboratory findings and ruling out common mimickers such as late-onset rheumatoid arthritis and pseudogout, among others (seen in figure). Learn more: https://www.nejm.org/doi/full/10.1056/NEJMcp2506817
Could patients with T2D who are chronically ill and have severe insulin resistance take either daily or weekly insulin?
The hosts of the Beyond Journal Club podcast, a collaboration between @COREIMpodcast and NEJM Group, discuss the QWINT-1 trial and review the T2D medication toolkit clinicians use every day. Read the show notes and listen to the latest episode: https://www.coreimpodcast.com/2026/02/11/insulin-and-qwint-1-trial/
📖 Further reading:
Original Article by J. Rosenstock et al.: Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy (QWINT-1 trial) https://www.nejm.org/doi/full/10.1056/NEJMoa2502796
Phase 3 RECITE trial: Chemotherapy-induced thrombocytopenia can lead to dose reductions or delays in cancer treatment. Research evaluating romiplostim for persistent CIT is summarized in a new Quick Take video. https://www.nejm.org/do/10.1056/NEJMdo008400/full/
This week's Image Challenge: A 33-year-old pregnant woman with previously well-controlled atopic dermatitis presents at 34 weeks’ gestation with a 3-day history of fever and an itchy, painful rash. What is the likely diagnosis? Read the full description and submit your answer: https://www.nejm.org/image-challenge?ci=20260312
Perspective by Nikhil A. Patel, MD, MPH, Amy Hunter, MSW, and Royce B. Murray, JD: Effects of Pervasive Immigration Enforcement on Children’s Health https://www.nejm.org/doi/full/10.1056/NEJMp2601176 #MedicalEthics #Pediatrics
In a new interview, @AbbasHassanMD, PhD, discusses the gap between the services that residents and fellows provide and the revenue that hospitals can capture. Listen to the full interview with NEJM Executive Managing Editor Stephen Morrissey (@srm128): https://www.nejm.org/do/10.1056/NEJMdo008436/full/
In an @NEJM Image in Clinical Medicine, a maculopapular exanthem is seen on a man’s face and trunk. Read the comment from Deputy Editor Ann Cheung, MD, MBA, MS: https://clinician.nejm.org/primary-measles-infection-CLINicmNA59879
#measles
A 49-year-old woman presented with a 6-month history of an itchy lump on her vulva. Examination showed a painless purple mass originating in the labia minora on the left side.
Read the full case details in the Images in Clinical Medicine article “Vulvar Melanoma with Vaginal Extension”: https://nej.md/3NvfoWW
#Oncology #OBGYN
Apixaban and rivaroxaban are the most frequently used oral anticoagulants for acute venous thromboembolism, but data on the difference in bleeding risk between the drugs are lacking. Research findings from the COBRRA trial are summarized in a new Quick Take video. https://www.nejm.org/do/10.1056/NEJMdo008398/full/
The authors of a new Perspective argue that CMS billing rules create a wide gap between the services trainees provide and the revenue hospitals can capture for those services. Competency-based billing could help close this gap. Read the Perspective by @AbbasHassanMD, PhD, and Jennifer F. Waljee, MD, MPH: https://www.nejm.org/doi/full/10.1056/NEJMp2514693
A 33-year-old pregnant woman with previously well-controlled atopic dermatitis presented to the emergency department at 34 weeks’ gestation with a 3-day history of fever and an itchy, painful rash. A lesion had first developed on her lip, after which skin lesions had appeared across her face and body, sparing the ocular, oral, and genital mucosa. Similar lesions were scattered across the chest, arms, and palms. What is the most likely diagnosis? https://nej.md/IC03122026
In a new Voices post, @PaulSaxMD rounds up key takeaways from #CROI2026, the leading HIV research conference. See the highlights: https://voices.nejm.org/doi/full/10.1056/VOICESpost2600002
A new Clinical Practice article summarizes the diagnosis and management of polymyalgia rheumatica in adults older than 50 years of age, emphasizing clinical diagnosis, glucocorticoids as first-line therapy, relapses, and glucocorticoid-sparing options.
Read the full case details in the Clinical Practice article “Polymyalgia Rheumatica” by Christian Dejaco, MD, PhD, and Eric L. Matteson, MD, MPH, from Medical University Graz; Hospital of Brunico (@SabesAsdaaBZ), Teaching Hospital of the Paracelsus Medical University; and Mayo Clinic College of Medicine and Science: https://www.nejm.org/doi/full/10.1056/NEJMcp2506817
Original Article: Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis (phase 3 TETON-2 trial) https://www.nejm.org/doi/full/10.1056/NEJMoa2512911
#Pulmonology #CriticalCare
A video shows the administration of DB-OTO, an adeno-associated virus 1 gene therapy that delivers OTOF cDNA to treat congenital deafness.
Watch the full video and read the accompanying article: https://www.nejm.org/doi/full/10.1056/NEJMoa2400521
#Otolaryngology
Paul Van de Heyning, MD, PhD, and Vincent Van Rompaey, MD, PhD, describe the scientific foundations of a study of gene therapy for hearing loss caused by damaging variants in the gene 𝘖𝘛𝘖𝘍.
Read about the science behind the study: https://www.nejm.org/doi/full/10.1056/NEJMe2514326
Original Article: DB-OTO Gene Therapy for Inherited Deafness (CHORD study) https://www.nejm.org/doi/full/10.1056/NEJMoa2400521
Science behind the Study: Gene Therapy to Treat Profound Hearing Loss https://www.nejm.org/doi/full/10.1056/NEJMe2514326
#Genetics #Otolaryngology
New in the March 12/19, 2026, issue of NEJM:
Bleeding Risk with Apixaban vs. Rivaroxaban in Acute VTE (COBRRA trial) https://nej.md/4lp5N0d
Romiplostim for Chemotherapy-Induced Thrombocytopenia (phase 3 RECITE trial) https://nej.md/40rIYzG
DB-OTO Gene Therapy for Inherited Deafness (CHORD study) https://nej.md/4o7ky8f
Fixed-Duration vs. Continuous Treatment for CLL (phase 3 CLL17 trial) https://nej.md/3KiZKwl
Subscribe to NEJM for the latest medical research: https://nej.md/subscribe
RECITE: In a phase 3 trial in patients with persistent chemotherapy-induced thrombocytopenia, 84% of those receiving romiplostim had no chemotherapy dose modifications, as compared with 36% of those receiving placebo (odds ratio, 10.16). Full trial results: https://www.nejm.org/doi/full/10.1056/NEJMoa2511882
Editorial: Thrombopoietin-Receptor Agonists in Chemotherapy-Induced Thrombocytopenia https://www.nejm.org/doi/full/10.1056/NEJMe2517578
In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period.
Full COBRRA trial results: https://www.nejm.org/doi/full/10.1056/NEJMoa2510703
The authors of a new Perspective argue that the types of immigration-enforcement actions being taken in the United States can activate children’s stress-response systems, disrupting neurodevelopment, immune function, and emotional regulation. Learn more: https://www.nejm.org/doi/full/10.1056/NEJMp2601176
In the phase 3 TETON-2 trial involving patients with idiopathic pulmonary fibrosis, inhaled treprostinil was associated with a smaller decline in forced vital capacity and a lower risk of clinical worsening than placebo over 52 weeks. Full trial results: https://www.nejm.org/doi/full/10.1056/NEJMoa2512911
For a patient with hypertension, would you recommend a systolic blood-pressure target of less than 120 mm Hg and or a target of less than 140 mm Hg? Vote on the best option: https://www.nejm.org/doi/full/10.1056/NEJMclde2505268
Original Article: Zorevunersen in Children and Adolescents with Dravet Syndrome https://www.nejm.org/doi/full/10.1056/NEJMoa2506295
Science behind the Study: Toward a Disease-Modifying Therapy for Dravet Syndrome https://www.nejm.org/doi/full/10.1056/NEJMe2515874
#Neurology #Genetics
Perspective by Alexandra Alvarez, MD, Caroline E. Sloan, MD, and Peter A. Ubel, MD (@peterubel): Debt by Design — Navigating the Hazards of Medical Credit Cards https://www.nejm.org/doi/full/10.1056/NEJMp2514612
#HealthPolicy
Neoadjuvant gemcitabine–oxaliplatin, lenvatinib, and anti–PD-1 antibody led to longer event-free survival than surgery alone in resectable high-risk intrahepatic cholangiocarcinoma, with mainly low-grade adverse events. Full phase 2–3 ZSAB-neoGOLP trial results and Research Summary: https://www.nejm.org/doi/full/10.1056/NEJMoa2513918
Images in Clinical Medicine: Trigeminal Trophic Syndrome https://www.nejm.org/doi/full/10.1056/NEJMicm2512031
#DermTwitter #Neurology
Original Article: Finerenone in Type 1 Diabetes and Chronic Kidney Disease (phase 3 FINE-ONE trial) https://www.nejm.org/doi/full/10.1056/NEJMoa2512854
Editorial: Finerenone for Diabetic Kidney Disease in Type 1 Diabetes — A Fine Answer? https://www.nejm.org/doi/full/10.1056/NEJMe2600575
#Endocrinology #Nephrology
Perspective by Jose F. Figueroa, MD, MPH (@joefigs2), and Ellen Meara, PhD: From Equity to Efficiency — Navigating Changes to the AHEAD Model https://www.nejm.org/doi/full/10.1056/NEJMp2514355
#HealthPolicy #MedicalEthics
Adaptive radiotherapy involves modifying treatment plans to account for changes in anatomical geometry that are not adequately mitigated with changes in alignment. Online adaptive radiotherapy capitalizes on advances in image guidance, real-time tumor tracking, and the enhanced speed of multiple steps in radiotherapy planning and delivery workflows (seen in image).
Learn more in the Review Article “Effects of Radiotherapy in Normal Tissue” by @DeborahCitrin, MD, and Robert D. Timmerman, MD (@BobTimmermanMD), from the National Cancer Institute and @UTSWMedCenter: https://www.nejm.org/doi/full/10.1056/NEJMra2506017
𝐍𝐨𝐰 𝐚𝐯𝐚𝐢𝐥𝐚𝐛𝐥𝐞 𝐢𝐧 𝑵𝑬𝑱𝑴 𝑬𝒗𝒊𝒅𝒆𝒏𝒄𝒆!
A new Public Health Alerts report, published in partnership with @CIDRAP: Tobacco Product Use among U.S. Adults, 2023–2024 https://eviden.cc/410uOp6
In STEMI with multivessel disease, immediate iFR-guided PCI of nonculprit lesions was not superior to deferred cardiac stress MRI–guided PCI in reducing death, reinfarction, or hospitalization for heart failure at 3 years. Full iMODERN trial and Research Summary: https://www.nejm.org/doi/full/10.1056/NEJMoa2512918